ClinicalTrials.gg
TerminatedNCT03332836Updated Apr 1, 2021

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

A Phase 1 interventional study of HM12460A in Type 2 Diabetes Mellitus, sponsored by Hanmi Pharmaceutical Company Limited. Terminated at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-04-01.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sopnsor decision

From the registry’s dates

  • Primary completion was Jan 2019, 7 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited — 2 open to participants now, 2 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Hanmi Pharmaceutical Company Limited.

Enrollment
10th of 10
21 · median 102
Started
2017
with 1 other
Phase 1
5 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 5 in phase 1, and was the 5th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, or all of them as a file.
02

Study summary

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus
  • Female subjects must be non-pregnant and non-lactating

Exclusion criteria

Exclusion Criteria:

  • Recurrent severe hypoglycemia or hypoglycemic unawareness or recent severe ketoacidosis, as judged by the Investigator
  • Pregnant or lactating women
  • Participation in an study within 30 days prior to dosing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Single dose subcutaneous administration (Dose A)

    Biological: HM12460A

  • Experimental
    Cohort 2

    Single dose subcutaneous administration (Dose B)

    Biological: HM12460A

  • Experimental
    Cohort 3

    Single dose subcutaneous administration (Dose C)

    Biological: HM12460A

Interventions

  • BiologicalHM12460A

    HM12460A is a long-acting insulin

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products.

    Time frame: 1 month

Secondary outcomes

  1. Cmax of HM12460A

    - Maximum concentration of HM12460A over the entire dosing period

    Time frame: 1 month

  2. AUC of HM12460A

    - Area Under the Curve of HM12460A over the entire dosing period

    Time frame: 1 month

07

Study locations

1 site
  • Hanmi Investigative Site
    Chula Vista, California 91911, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Jan 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Nov 6, 2017
StartActual
Oct 25, 2017
Primary completionActual
Jan 30, 2019
CompletionActual
Sep 30, 2020
Last update
Apr 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03332836
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Oct 25, 2017
Primary completion
Jan 30, 2019
Completion
Sep 30, 2020
Last update
Apr 1, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HM12460A

Start the discussion